Keywords: Shire, Gaucher disease, velaglucerase alfa, enzyme replacement therapy

Shire’s Gaucher disease drug enters fast-track EU approval process

Article | 27 November 2009

Print This

Britain’s biopharmaceuticals group Shire is racing to end a shortage of drugs to treat Type 1 Gaucher disease, a condition ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in